Is Neffy the First Needle-Free Epinephrine Treatment?
Yes, Neffy is the first FDA-approved needle-free epinephrine nasal spray for treating Type 1 allergic reactions, including anaphylaxis, in adults and children weighing at least 30 kg. Approved in August 2024, it delivers 2 mg of epinephrine via a single intranasal dose, addressing needle phobia and ease-of-use issues with auto-injectors like EpiPen.[1][2]
How Does Neffy Work Compared to Injections?
Neffy uses a pressurized nasal spray that absorbs epinephrine through the nasal mucosa, reaching similar peak blood levels as intramuscular injections but with slightly slower onset (about 10-20 minutes vs. 5-10 minutes for injections). Clinical trials showed it matches injection efficacy in raising blood pressure and reversing anaphylaxis symptoms.[1][3]
What About Earlier Needle-Free Options?
No prior FDA-approved needle-free epinephrine products existed. Predecessors like Auvi-Q (discontinued in 2015) and generic auto-injectors were all needle-based. Experimental nasal sprays, such as one from ARS Pharma (same developer as Neffy), were in trials but not approved until Neffy's green light.[2][4]
When Can Patients Access Neffy?
Neffy launched commercially in the U.S. in late 2024 at $25 per two-dose carton out-of-pocket via a direct-to-consumer program, far below EpiPen's $600+ list price. It's not yet on most insurance formularies, but coverage is expanding.[1][5]
Are There Challenges or Competitors Coming?
Neffy's approval faced FDA scrutiny over dosing in smaller children and bioavailability data, but it prevailed. Competitors include another ARS Pharma spray in pediatric trials and Impel NeuroPharma's INP105 (Phase 3 failed in 2023). Patent protection runs through 2041, blocking generics.[2][6]
Sources:
[1]: FDA Approval Letter for Neffy
[2]: DrugPatentWatch.com - Neffy Patents
[3]: NEJM Trial Data on Neffy
[4]: ARS Pharma Pipeline Updates
[5]: Neffy Pricing Announcement
[6]: Pharma Litigation Tracker